In a welcome move, Progyny saw its Relative Strength Rating rise from 68 to 72 on Wednesday.
How To Invest In Stocks In Both Bull And Bear Markets
This proprietary rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains typically have an 80 or higher RS Rating as they launch their largest runs. See if Progyny can continue to rebound and clear that threshold.
Progyny is building a consolidation with a 26.76 buy point. See if it can break out in volume at least 40% higher than normal.
EPS growth fell last quarter from 31% to 23%, but sales rose from 11% to 17%.
Progyny earns the No. 2 rank among its peers in the Medical-Services industry group. Hims & Hers Health is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
